title: [Current therapeutic progress in oncology: the development of targeted therapies].
abstract: Over the last decades, significant advances were make in basic research as concerns the malignant transformation of normal cells. As a result, new targets for treatment were identified. "Targeted therapies" indicates that treatments are directed against specific molecular targets that play a major role in the activation of cell division and in the growth and dissemination of tumors. In particular, targeted therapies were developed against epithelial growth factor receptors and angiogenesis. We can expect specifise therapies against many other targets in the near future. Several drugs have obtained a marketing license. Predictive factors for tumor response and long term outcome should be developed for a better selection of the patient population who will benefit from these treatments. New imaging techniques are under development in order to assess the molecular response to these new approaches.
authors.affiliation: Service d'Oncologie Médicale, CHU Sart-Tilman, Liège. christinegennigens@yahoo.com
authors.forename: C
authors.initials: C
authors.lastname: Gennigens
authors.forename: B
authors.initials: B
authors.lastname: Sautois
authors.forename: A
authors.initials: A
authors.lastname: Rorive
authors.forename: G
authors.initials: G
authors.lastname: Fillet
authors.forename: G
authors.initials: G
authors.lastname: Jerusalem
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D017978:Receptors, Growth Factor / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D017978:Receptors, Growth Factor